Table 1 Clinical characteristics of patients in our cohort
| Â | Cohort | Antithrombotic treatment | |
|---|---|---|---|
|  | n = 1814 (100%) | Yes n = 672 (37.0%) | No n = 1142 (63.0%) |
Female, n (%) | 959 (52.9) | 284 (42.3) | 675 (59.1) |
Age, yrs, n (%) | Â | Â | Â |
  < 20 | 13 (0.7) | 3 (0.4) | 10 (0.9) |
  20–34 | 145 (8.0) | 19 (2.8) | 126 (11.0) |
  35–49 | 197 (10.9) | 35 (5.2) | 162 (14.2) |
  50–64 | 383 (21.1) | 120 (17.9) | 263 (23.0) |
  ≥ 65 | 1076 (59.3) | 495 (73.6) | 581 (50.9) |
Age, median yrs (IQR) | 68 (55–79) | 73 (64–81) | 65 (49–76) |
Anticoagulant or platelet inhibitor, n (%)* | Â | Â | Â |
  Any anticoagulant | 396 (21.8) | 396 (58.9) | – |
  LMWH therapeutic | 95 (5.2) | 95 (14.1) | – |
  LMWH prophylactic | 214 (11.8) | 214 (31.8) | – |
  Non-LMWH anticoagulants | 102 (5.6) | 102 (15.2) | – |
  Any platelet inhibitor | 328 (18.1) | 328 (48.8) | – |
  Non-ASA platelet inhibitor | 68 (3.7) | 68 (10.1) | – |
  ASA | 304 (16.8) | 304 (45.2) | – |
Pathogen in urine, n (%)* | Â | Â | Â |
  Any Gram-negative | 1579 (86.5) | 567 (84.4) | 1003 (87.8) |
  Any E. coli | 1078 (59.4) | 333 (49.6) | 745 (65.2) |
  Any Gram-negative other than E. coli | 547 (30.2) | 254 (37.8) | 293 (25.7) |
  Any Gram-positive | 333 (18.4) | 155 (23.1) | 278 (15.6) |
  Any other pathogen than E. coli   (both gram-negative and gram-positive) | 834 (46.0) | 383 (57.0) | 451 (39.5) |
  ≥ 2 pathogens in urine | 165 (9.1) | 82 (12.2) | 83 (7.3) |
Clinical presentation, n (%)* | Â | Â | Â |
  Fever | 1806 (99.6) | 671 (99.9) | 1135 (99.4) |
  Urinary catheter | 368 (20.3) | 211 (31.4) | 157 (13.7) |
  CRP levels, median mg/L (IQR) | 84.5 (38–162) | 84 (40–161) | 85 (36–162) |
  WBC count, median count × 10.9/L (IQR) | 11.6 (8.2–15.5) | 12.0 (8.6–15.7) | 11.4 (7.9–15.4) |
Comorbidities, n (%)* | Â | Â | Â |
  Diabetes | 295 (16.3) | 148 (22.0) | 147 (12.9) |
  Malignancy | 583 (32.1) | 231 (34.8) | 352 (30.8) |
  Hypertension | 521 (28.7) | 287 (42.7) | 234 (20.5) |
  Chronic Renal Failure | 165 (9.1) | 96 (14.3) | 69 (6.0) |
  Chronic Liver Disease | 25 (1.4) | 6 (0.9) | 19 (1.7) |
  Congestive Heart Failure | 208 (11.5) | 122 (18.2) | 86 (7.5) |
  Tachycardia arrhythmia | 263 (14.5) | 160 (23.8) | 103 (9.0) |
  Atrial fibrillation | 249 (13.7) | 153 (22.8) | 96 (8.4) |
  Cardiovascular disease | 320 (17.6) | 229 (34.1) | 91 (8.0) |
  Thromboembolism | 128 (7.1) | 83 (12.4) | 45 (3.9) |
  Coagulopathy | 71 (3.9) | 19 (2.8) | 52 (4.6) |
  BMI |  |  |  |
   < 18.5 kg/m2 | 241 (13.3) | 96 (14.3) | 145 (12.7) |
   18.5–25 kg/m2 | 405 (22.3) | 156 (23.2) | 249 (21.8) |
   25–30 kg/m2 | 369 (20.3) | 165 (24.6) | 204 (17.9) |
   ≥ 30 kg/m2 | 198 (10.9) | 93 (13.8) | 105 (9.2) |
Missing | 601 (33.1) | 162 (24.1) | 439 (38.4) |